Early Detection of Non-Small Cell Lung Cancer by Using a 12-microRNA Panel and a Nomogram for Assistant Diagnosis

Wang, Weidong; Chen, Dongni; Chen, Weiwei; Xin, Ziya; Huang, Zirui; Zhang, Xuewen; Xi, Kexing; Wang, Gongming; Zhang, Rusi; Zhao, Dechang; Liu, Li

doi:10.3389/fonc.2020.00855

Cited by 16 publications

(11 citation statements)

References 38 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTCs in the blood could serve as effective screening and diagnostic markers to discriminate small malignant pulmonary nodules from benign lesions [ 54 , 56 ]. The profiling of circulating microRNAs has promising accuracy for discriminating lung cancer patients from healthy controls and could be developed as a supplement in future screening [ 51 , 84 ]. Recently, integrative multi-analytical models combining clinical features and multiple biomarkers have achieved a better balance of predictive sensitivity and specificity [ 16 , 40 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer

Shen

Jin

Zhao

et al. 2022

BMC Med

View full text Add to dashboard Cite

Background Liquid biopsy has been widely researched for early diagnosis, prognostication and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for early-stage non-small cell lung cancer (NSCLC). Methods We performed a meta-analysis and systematic review to evaluate diagnostic and prognostic values of liquid biopsy for early-stage NSCLC, regarding the common biomarkers, circulating tumor cells, circulating tumor DNA (ctDNA), methylation signatures, and microRNAs. Cochrane Library, PubMed, EMBASE databases, ClinicalTrials.gov, and reference lists were searched for eligible studies since inception to 17 May 2022. Sensitivity, specificity and area under the curve (AUC) were assessed for diagnostic values. Hazard ratio (HR) with a 95% confidence interval (CI) was extracted from the recurrence-free survival (RFS) and overall survival (OS) plots for prognostic analysis. Also, potential predictive values and treatment response evaluation were further investigated. Results In this meta-analysis, there were 34 studies eligible for diagnostic assessment and 21 for prognostic analysis. The estimated diagnostic values of biomarkers for early-stage NSCLC with AUCs ranged from 0.84 to 0.87. The factors TNM stage I, T1 stage, N0 stage, adenocarcinoma, young age, and nonsmoking contributed to a lower tumor burden, with a median cell-free DNA concentration of 8.64 ng/ml. For prognostic analysis, the presence of molecular residual disease (MRD) detection was a strong predictor of disease relapse (RFS, HR, 4.95; 95% CI, 3.06–8.02; p < 0.001) and inferior OS (HR, 3.93; 95% CI, 1.97–7.83; p < 0.001), with average lead time of 179 ± 74 days between molecular recurrence and radiographic progression. Predictive values analysis showed adjuvant therapy significantly benefited the RFS of MRD + patients (HR, 0.27; p < 0.001), while an opposite tendency was detected for MRD − patients (HR, 1.51; p = 0.19). For treatment response evaluation, a strong correlation between pathological response and ctDNA clearance was detected, and both were associated with longer survival after neoadjuvant therapy. Conclusions In conclusion, our study indicated liquid biopsy could reliably facilitate more precision and effective management of early-stage NSCLC. Improvement of liquid biopsy techniques and detection approaches and platforms is still needed, and higher-quality trials are required to provide more rigorous evidence prior to their routine clinical application.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer

Shen

Jin

Zhao

et al. 2022

BMC Med

View full text Add to dashboard Cite

show abstract

“…In NSCLC patients, miR-221 levels increase significantly in plasma, suggesting its potential as a therapeutic target or non-invasive marker for early diagnosis and screening of NSCLC [ 214 ]. Wang et al (2020) also suggested miR-221 as one of the biomarkers for early detection of NSCLC [ 215 ].…”

Section: Tumor Enhancer Mirnamentioning

confidence: 99%

MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential

et al. 2022

View full text Add to dashboard Cite

Lung cancer is the dominant emerging factor in cancer-related mortality around the globe. Therapeutic interventions for lung cancer are not up to par, mainly due to reoccurrence/relapse, chemoresistance, and late diagnosis. People are currently interested in miRNAs, which are small double-stranded (20–24 ribonucleotides) structures that regulate molecular targets (tumor suppressors, oncogenes) involved in tumorigeneses such as cell proliferation, apoptosis, metastasis, and angiogenesis via post-transcriptional regulation of mRNA. Many studies suggest the emerging role of miRNAs in lung cancer diagnostics, prognostics, and therapeutics. Therefore, it is necessary to intensely explore the miRNOME expression of lung tumors and the development of anti-cancer strategies. The current review focuses on the therapeutic, diagnostic, and prognostic potential of numerous miRNAs in lung cancer.

show abstract

“…To date, several important miRNAs have been identified for regulating muscle growth and development, such as miR-205, miR-126, miR-60, miR-75, miR-133, miR-499, etc. [ 2 ]. MyoD1 , a marker gene of muscle differentiation, is regulated by miR-1 and miR-206 [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

MiR-22-3p Inhibits Proliferation and Promotes Differentiation of Skeletal Muscle Cells by Targeting IGFBP3 in Hu Sheep

Wang

Cao

et al. 2022

Animals

View full text Add to dashboard Cite

The growth and development of skeletal muscle require a series of regulatory factors. MiRNA is a non-coding RNA with a length of about 22 nt, which can inhibit the expression of mRNA and plays an important role in the growth and development of muscle cells. The role of miR-22-3p in C2C12 cells and porcine skeletal muscle has been reported, but it has not been verified in Hu sheep skeletal muscle. Through qPCR, CCK-8, EdU and cell cycle studies, we found that overexpression of miR-22-3p inhibited proliferation of skeletal muscle cells (p < 0.01). The results of qPCR and immunofluorescence showed that overexpression of miR-22-3p promoted differentiation of skeletal muscle cells (p < 0.01), while the results of inhibiting the expression of miR-22-3p were the opposite. These results suggested that miR-22-3p functions in growth and development of sheep skeletal muscle cells. Bioinformatic analysis with mirDIP, miRTargets, and RNAhybrid software suggested IGFBP3 was the target of miR-22-3p, which was confirmed by dual-luciferase reporter system assay. IGFBP3 is highly expressed in sheep skeletal muscle cells. Overexpression of IGFBP3 was found to promote proliferation of skeletal muscle cells indicated by qPCR, CCK-8, EdU, and cell cycle studies (p < 0.01). The results of qPCR and immunofluorescence experiments proved that overexpression of IGFBP3 inhibited differentiation of skeletal muscle cells (p < 0.01), while the results of interfering IGFBP3 with siRNA were the opposite. These results indicate that miR-22-3p is involved in proliferation and differentiation of skeletal muscle cells by targeting IGFBP3.

show abstract

Early Detection of Non-Small Cell Lung Cancer by Using a 12-microRNA Panel and a Nomogram for Assistant Diagnosis

Abstract: Background: We previously identified a 12-microRNA (miRNA) panel

Cited by 16 publications

References 38 publications

Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer

Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer

MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential

MiR-22-3p Inhibits Proliferation and Promotes Differentiation of Skeletal Muscle Cells by Targeting IGFBP3 in Hu Sheep

Contact Info

Product

Resources

About